[go: up one dir, main page]

CY1112493T1 - Ενωση 3-υποκατεστημενης-[1,2,3]-βενζοτριαζινονης για την ενισχυση των γλουταμινεργικων συναπτικων αποκρισεων - Google Patents

Ενωση 3-υποκατεστημενης-[1,2,3]-βενζοτριαζινονης για την ενισχυση των γλουταμινεργικων συναπτικων αποκρισεων

Info

Publication number
CY1112493T1
CY1112493T1 CY20111101287T CY111101287T CY1112493T1 CY 1112493 T1 CY1112493 T1 CY 1112493T1 CY 20111101287 T CY20111101287 T CY 20111101287T CY 111101287 T CY111101287 T CY 111101287T CY 1112493 T1 CY1112493 T1 CY 1112493T1
Authority
CY
Cyprus
Prior art keywords
disorders
treatment
compound
glutaminergic
boost
Prior art date
Application number
CY20111101287T
Other languages
English (en)
Inventor
Alexis Cordi
Gary Rogers
Rudolf Mueller
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of CY1112493T1 publication Critical patent/CY1112493T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Αυτή η εφεύρεση αναφέρεται στην πρόληψη και θεραπεία της εγκεφαλικής ανεπάρκειας, συμπεριλαμβανομένης της ενίσχυσης της λειτουργίας των υποδοχέων στις συνάψεις στο εγκεφαλικό δίκτυο υπεύθυνες για συμπεριφορές υψηλότερης τάξης. Αυτά τα εγκεφαλικά δίκτυα εμπλέκονται σε γνωστικές ικανότητες που σχετίζονται με εξασθένηση μνήμης, όπως παρατηρείται σε μια ποικιλία ανιών, και σε ανισορροπίες στη νευρωνική δραστηριότητα μεταξύ διαφορετικών περιοχών του εγκεφάλου, όπως συνιστάται σε διαταραχές όπως η νόσος του Ρarkinson, σχιζοφρένεια και συναισθηματικές διαταραχές. Κατά μια συγκεκριμένη άποψη, η παρούσα εφεύρεση σχετίζεται με μια ένωση χρήσιμη για τη θεραπεία τέτοιων παθήσεων, και με μεθόδους χρήσης αυτής της ένωσης για μια τέτοια θεραπεία.
CY20111101287T 2007-01-03 2011-12-28 Ενωση 3-υποκατεστημενης-[1,2,3]-βενζοτριαζινονης για την ενισχυση των γλουταμινεργικων συναπτικων αποκρισεων CY1112493T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87850307P 2007-01-03 2007-01-03
US92143307P 2007-04-02 2007-04-02
EP07868093A EP2144506B1 (en) 2007-01-03 2007-12-28 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses

Publications (1)

Publication Number Publication Date
CY1112493T1 true CY1112493T1 (el) 2015-12-09

Family

ID=39608956

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111101287T CY1112493T1 (el) 2007-01-03 2011-12-28 Ενωση 3-υποκατεστημενης-[1,2,3]-βενζοτριαζινονης για την ενισχυση των γλουταμινεργικων συναπτικων αποκρισεων

Country Status (37)

Country Link
US (1) US8173644B2 (el)
EP (1) EP2144506B1 (el)
JP (1) JP5139446B2 (el)
CN (1) CN101616592B (el)
AP (1) AP2502A (el)
AR (1) AR064740A1 (el)
AT (1) ATE527269T1 (el)
AU (1) AU2007342365B2 (el)
BR (1) BRPI0720749A2 (el)
CA (1) CA2674460C (el)
CR (1) CR10906A (el)
CU (1) CU23804B7 (el)
CY (1) CY1112493T1 (el)
DK (1) DK2144506T3 (el)
EA (1) EA017437B1 (el)
EC (1) ECSP099499A (el)
ES (1) ES2374995T3 (el)
GE (1) GEP20125438B (el)
GT (1) GT200900189A (el)
HN (1) HN2009001268A (el)
HR (1) HRP20110970T1 (el)
IL (1) IL199651A (el)
MA (1) MA31160B1 (el)
ME (1) ME00819B (el)
MX (1) MX2009007242A (el)
MY (1) MY154877A (el)
NI (1) NI200900131A (el)
NZ (1) NZ578293A (el)
PL (1) PL2144506T3 (el)
PT (1) PT2144506E (el)
RS (1) RS52108B (el)
SG (1) SG163545A1 (el)
SI (1) SI2144506T1 (el)
SV (1) SV2009003322A (el)
TN (1) TN2009000277A1 (el)
WO (1) WO2008085506A1 (el)
ZA (1) ZA200904826B (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2114158B1 (en) * 2007-01-03 2012-08-08 Cortex Pharmaceuticals, Inc. 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
TW200911768A (en) * 2007-05-17 2009-03-16 Cortex Pharma Inc Di-substituted amides for enhancing glutamatergic synaptic responses
US8168632B2 (en) 2007-08-10 2012-05-01 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for the treatment of respiratory disorders
US8263591B2 (en) 2007-08-10 2012-09-11 Cortex Pharmaceuticals, Inc. Bicyclic amides for enhancing glutamatergic synaptic responses
US20110257186A1 (en) * 2010-04-15 2011-10-20 Staubli Ursula V Compositions and methods for treating visual disorders
WO2013075624A1 (zh) 2011-11-22 2013-05-30 北京哈三联科技股份有限公司 甘氨酸重摄取抑制剂及其应用
FR3019464B1 (fr) 2014-04-07 2016-05-06 Servier Lab Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
FR3034019B1 (fr) 2015-03-26 2017-03-17 Servier Lab Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un antidepresseur et les compositions pharmaceutiques qui la contiennent
TN2017000508A1 (en) 2015-06-26 2019-04-12 Takeda Pharmaceuticals Co 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
CN106226509B (zh) * 2016-08-12 2019-09-06 中国人民解放军第四军医大学 一种在小鼠前扣带回皮层诱发dse现象的方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3723436A (en) * 1971-02-25 1973-03-27 Sun Oil Co Process for aromatic lactams
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
FR2597103B1 (fr) * 1986-04-15 1988-12-16 Provesan Sa Procede de preparation de derives d'oxazinobenzothiazine 6,6-dioxyde
DK1156043T3 (da) 1992-07-24 2004-03-01 Univ California Lægemidler, der forøger synaptiske reaktioner formidlet af ampa-receptorer
US5962477A (en) * 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
ATE174915T1 (de) * 1994-10-31 1999-01-15 Merck Patent Gmbh Benzylpiperidinderivate mit hoher affinität zu bindungsstellen von aminosäure-rezeptoren
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
WO1998011892A1 (en) 1996-09-17 1998-03-26 The Regents Of The University Of California Positive ampa receptor modulation to enhance brain neurotrophic factor expression
US6110935A (en) * 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
US5985871A (en) * 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response
IL137720A0 (en) 1998-02-18 2001-10-31 Neurosearch As Compounds and their use as positive ampa receptor modulators
US6713474B2 (en) * 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
US6303542B1 (en) * 2000-08-18 2001-10-16 Rohm And Haas Company Herbicidal 3-substituted-phenyl-1,2,3-benzotriazin-4-ones
EP1448537A4 (en) * 2001-11-26 2005-05-04 Cortex Pharma Inc CARBONYLBENZOXAZINIC COMPOUNDS ENHANCING SYNAPTIC GLUTAMATERGIC RESPONSES
JP2003238555A (ja) * 2002-02-20 2003-08-27 Sumitomo Pharmaceut Co Ltd 細胞死抑制剤
AUPS255202A0 (en) 2002-05-27 2002-06-13 Monash University Agents and methods for the treatment of disorders associated with motor neuron degeneration
BRPI0406736A (pt) * 2003-01-13 2005-12-20 Cortex Pharma Inc Método de tratar declìnico cognitivo devido à privação de sono e estresse
GB0317482D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
EP2114158B1 (en) * 2007-01-03 2012-08-08 Cortex Pharmaceuticals, Inc. 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
TW200911768A (en) * 2007-05-17 2009-03-16 Cortex Pharma Inc Di-substituted amides for enhancing glutamatergic synaptic responses
US8263591B2 (en) 2007-08-10 2012-09-11 Cortex Pharmaceuticals, Inc. Bicyclic amides for enhancing glutamatergic synaptic responses
EP2195303A4 (en) * 2007-09-20 2011-07-20 Cortex Pharma Inc 3-SUBSTITUTED 1,2,3-TRIAZIN-4-ONE AND 3-SUBSTITUTED 1,3-PYRIMIDIONE FOR INCREASING GLUTAMATERGIC SYNAPTIC REACTIONS

Also Published As

Publication number Publication date
AP2009004931A0 (en) 2009-08-31
EP2144506B1 (en) 2011-10-05
CU20090117A7 (es) 2011-10-05
ES2374995T3 (es) 2012-02-23
US8173644B2 (en) 2012-05-08
SG163545A1 (en) 2010-08-30
CU23804B7 (es) 2012-03-15
JP5139446B2 (ja) 2013-02-06
NI200900131A (es) 2010-03-11
EP2144506A4 (en) 2010-05-05
AU2007342365B2 (en) 2012-11-15
CN101616592A (zh) 2009-12-30
IL199651A (en) 2015-08-31
NZ578293A (en) 2012-01-12
HRP20110970T1 (hr) 2012-01-31
DK2144506T3 (da) 2012-03-05
GEP20125438B (en) 2012-03-26
SV2009003322A (es) 2010-02-05
RS52108B (sr) 2012-08-31
WO2008085506A1 (en) 2008-07-17
MY154877A (en) 2015-08-14
EA200900925A1 (ru) 2009-12-30
GT200900189A (es) 2011-08-02
CR10906A (es) 2009-10-23
EA017437B1 (ru) 2012-12-28
TN2009000277A1 (en) 2010-10-18
AP2502A (en) 2012-10-23
ECSP099499A (es) 2009-10-30
BRPI0720749A2 (pt) 2014-01-14
US20100137295A1 (en) 2010-06-03
MA31160B1 (fr) 2010-02-01
JP2010514838A (ja) 2010-05-06
CA2674460A1 (en) 2008-07-17
ZA200904826B (en) 2010-09-29
IL199651A0 (en) 2010-04-15
PT2144506E (pt) 2011-12-21
MX2009007242A (es) 2009-09-02
AU2007342365A1 (en) 2008-07-17
HK1140105A1 (en) 2010-10-08
CA2674460C (en) 2014-07-15
CN101616592B (zh) 2013-06-05
SI2144506T1 (sl) 2012-01-31
AR064740A1 (es) 2009-04-22
ME00819B (me) 2012-03-20
PL2144506T3 (pl) 2012-04-30
HN2009001268A (es) 2011-12-27
ATE527269T1 (de) 2011-10-15
EP2144506A1 (en) 2010-01-20

Similar Documents

Publication Publication Date Title
CY1112493T1 (el) Ενωση 3-υποκατεστημενης-[1,2,3]-βενζοτριαζινονης για την ενισχυση των γλουταμινεργικων συναπτικων αποκρισεων
CY1123734T1 (el) Καταστολη συμπληρωματος για βελτιωμενη αναγεννηση νευρου
CY1117317T1 (el) Αναστολεις κινασης janus για θεραπεια ξηροφθαλμιας και αλλων σχετικων με τον οφθαλμο ασθενειων
FR21C1031I2 (fr) Derives de la n4-phenyl-quinazoline-4-amine et composes similaires en tant que inhibiteurs de la kinase tyrosine erbb type i pour le traitement de maladies hyperproliferatives
CY1118660T1 (el) Συνθεσεις και μεθοδοι για την θεραπεια διαταραχων ματιων
BR112022003505A2 (pt) Composições e métodos para tratamento de distúrbios associados a dna repetitivo
DE602006008456D1 (de) Amylin und amylinagonisten für die behandlung von psychiatrischen erkrankungen und störungen
CY1118452T1 (el) Ενωσεις και συνθεσεις ως αναστολεις πρωτεϊνικης κινασης
EA200900937A1 (ru) Соединения 3-замещенного-[1,2,3]бензотриазинона для усиления глутаматергических синаптических ответов
ECSP10010230A (es) Derivados de isoxazolo-piridina
UY28011A1 (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
EA200900831A1 (ru) Модуляторы никотиновых ацетилхолиновых рецепторов
ECSP10010226A (es) Compuestos derivados de amina para tratar enfermedades y trastornos oftálmicos
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
CY1111206T1 (el) Βενζοθειοφαινια υποκατεστημενα με πιπεραζινη για την αγωγη διανοητικων διαταραχων
CY1112083T1 (el) Υποκαθιστουμενα ν-φαινυλο-διπυρρολιδινο καρβοξαμιδια και η θεραπευτικη τους χρηση
CY1112683T1 (el) Υποκατεστημενες καρβοξαμιδες ν-φαινυλ-διπυρρολιδινης και θεραπευτικες χρησεις τους
ATE424386T1 (de) Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
DK2332408T3 (da) Behandling af neurologiske sygdomme
WO2013067076A3 (en) Methods and compositions for neuroprotection
EP2350283A4 (en) COMPOUNDS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISORDERS OF THE CNS
BR0214425A (pt) Compostos carbonilbenzoxazina para aperfeiçoamento de respostas sinápticas glutamatérgicas
ATE494891T1 (de) Carbonylamino-derivate zur behandlung von entzündlicher darmerkrankung
BRPI0512732A (pt) formulações tópicas para tratamento de doenças alérgicas
GT200900150A (es) Nuevos compuestos azabiciclicos, un proceso para su preparacion y las composiciones farmaceuticas que los contienen.